Atle Fund Management AB Reduces Position in Bicara Therapeutics Inc. $BCAX

Atle Fund Management AB lessened its stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) by 45.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 111,363 shares of the company’s stock after selling 92,392 shares during the period. Atle Fund Management AB’s holdings in Bicara Therapeutics were worth $1,874,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the stock. Legal & General Group Plc grew its position in Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after purchasing an additional 1,233 shares during the last quarter. Invesco Ltd. lifted its stake in Bicara Therapeutics by 13.2% during the 2nd quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock valued at $157,000 after acquiring an additional 1,962 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Bicara Therapeutics during the 4th quarter valued at approximately $45,000. Larson Financial Group LLC lifted its stake in Bicara Therapeutics by 1,015.5% during the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after acquiring an additional 3,595 shares during the period. Finally, Tower Research Capital LLC TRC lifted its stake in Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after acquiring an additional 3,866 shares during the period.

Insider Buying and Selling at Bicara Therapeutics

In other news, insider David Raben sold 16,300 shares of Bicara Therapeutics stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $18.52, for a total value of $301,876.00. Following the transaction, the insider directly owned 55,286 shares of the company’s stock, valued at $1,023,896.72. The trade was a 22.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Claire Mazumdar sold 36,766 shares of Bicara Therapeutics stock in a transaction on Monday, March 9th. The shares were sold at an average price of $19.17, for a total transaction of $704,804.22. Following the completion of the transaction, the chief executive officer directly owned 339,392 shares in the company, valued at $6,506,144.64. The trade was a 9.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 186,810 shares of company stock valued at $3,712,908.

Bicara Therapeutics Trading Up 3.8%

BCAX stock opened at $20.03 on Wednesday. Bicara Therapeutics Inc. has a twelve month low of $7.80 and a twelve month high of $24.25. The company’s 50 day moving average is $21.06 and its two-hundred day moving average is $18.24. The stock has a market cap of $1.32 billion, a P/E ratio of -7.21 and a beta of -0.57.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). On average, equities research analysts predict that Bicara Therapeutics Inc. will post -3.37 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Wednesday, April 8th. Wall Street Zen lowered shares of Bicara Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. HC Wainwright boosted their price target on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Morgan Stanley boosted their price target on shares of Bicara Therapeutics from $36.00 to $37.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th. Finally, The Goldman Sachs Group boosted their price target on shares of Bicara Therapeutics from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Bicara Therapeutics has an average rating of “Moderate Buy” and an average price target of $30.27.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.